Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of overt hepatic encephalopathy
This quality standard covers preventing and identifying alcohol problems in the community. It includes policy and practice approaches to prevent harmful alcohol use in adults, young people and children. It is particularly relevant to local authorities, the police, and schools and colleges. It describes high-quality care in priority areas for improvement.
This guideline covers preventing children, young people and adults becoming overweight or obese. It outlines how the NHS, local authorities, early years’ settings, schools and workplaces can increase physical activity levels and make dietary improvements among their target populations.
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
Evidence-based recommendations on vemurafenib (Zelboraf) for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
Advice on the use of Oncentra Prostate v4.x for ultrasound-guided real-time HDR brachytherapy in men with localised prostate cancer to aid local decision-making
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in people with alcohol dependence
Evidence-recommendations on erythropoiesis-stimulation agents (epoetin alfa, beta, theta and zeta and darbepoetin alfa) for anaemia in people with cancer..
Evidence-based recommendations on imatinib (Glivec) for adjuvant treatment of gastrointestinal stromal tumours (cancers in the digestive track)
Interim methods guide for developing good practice guidance
Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis (MS/RRMS)
This quality standard covers the assessment and early management of fever with no obvious cause in babies and children (from birth to 5 years). It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on ipilimumab (YERVOY) for treating previously untreated advanced (unresectable or metastatic) melanoma (skin cancer)
Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure
Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes
Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis (RRMS/MS) in adults
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating active relapsing–remitting multiple sclerosis (MS)
Evidence-based recommendations on bortezomib (Velcade) for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell..
Evidence-based recommendations on aflibercept (Eylea) for visual impairment caused by macular oedema secondary to central retinal vein occlusion
Evidence-based recommendations on pixantrone (Pixuvri) for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema after prior therapy
Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C
Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)
Evidence-based recommendations on aflibercept (Eylea) solution for injection for treating wet age-related macular degeneration
Evidence-based recommendations on inserting customised exposed titanium implants, (without soft tissue cover) for complex orofacial (face) reconstruction
The number of people who self-harm has risen steadily over the past two decades, meaning the UK now has one of the highest rates in Europe.
Evidence-based recommendations on insertion of customised titanium implants, with soft tissue cover for orofacial (face and jaw) reconstruction
Evidence-based recommendations on mirabegron (Betmiga) for treating the symptoms of overactive bladder
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism
Symptom relief through the range of recommended drugs and treatments available should be the primary outcome for patients with ulcerative colitis, according to NICE.
Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion
A prompt diagnosis of social anxiety disorder is crucial in ensuring people access the most clinical and cost effective treatment, according to NICE.
Medicines optimisation: key therapeutic topics – Integrated process statement
Guide to the methods of technology appraisal 2013
Adults with hyperphosphataemia in chronic kidney disease should be offered a calcium-based phosphate binder as a first-line treatment in addition to dietary management, says NICE.
This quality standard covers diagnosing, treating and managing epilepsy and seizures in children and young people (under 18). It describes high-quality care in priority areas for improvement.
This quality standard covers diagnosing, treating and managing epilepsy and seizures in adults (aged 18 and older). It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema
Key therapeutic topics – Medicines management options for local implementation: Interim process statement
Evidence-based recommendations on the WatchBP Home A for opportunistically detecting atrial fibrillation (AF) when diagnosing and managing hypertension
Greater awareness of hepatitis B and C is needed so that more people who are at risk can be tested and treated for the viruses, according to latest guidance from NICE.
Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation (AF)
Obesity should be tackled by encouraging different organisations to work together through a 'community-wide' approach, according to latest guidance from NICE.
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke (AIS)
Methods for the development of NICE public health guidance (third edition)
The NICE public health guidance development process (third edition)
GPs should use either the FRAX or QFracture tools to estimate fracture risk in at-risk patients, NICE says.